Olanzapine pharmacokinetics in pediatric and adolescent inpatients with childhood-onset schizophrenia

Journal of Clinical Psychopharmacology

Volumn 20, Issue 2, 2000, Pages 220-225

  Grothe, Dale R ^a   Calis, Karim A ^a,f   Jacobsen, Leslie ^b   Kumra, Sanjiv ^a   Devane, C Lindsay ^c   Rapoport, Judith L ^a   Bergstrom, Richard F ^d,e   Kurtz, Darcie L ^d  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^d ELI LILLY AND COMPANY   (United States)

^e INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLONAZEPAM; LORAZEPAM; OLANZAPINE;

ADOLESCENT; ADULT; ARTICLE; CHILD PSYCHIATRY; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; FEMALE; HOSPITAL PATIENT; HUMAN; MALE; ONSET AGE; PRACTICE GUIDELINE; PRIORITY JOURNAL; SCHIZOPHRENIA; SCHOOL CHILD;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; METABOLIC CLEARANCE RATE; PATIENT ADMISSION; PIRENZEPINE; SCHIZOPHRENIA, CHILDHOOD; TREATMENT OUTCOME;

EID: 0034115771     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-200004000-00015     Document Type: Article

References (26)

1. Beasley CM Jr, Tollefson G, Tran P, Satterlee W, Sanger T, Hamilton S. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 1996;14:111-23.
2. Beasley CM Jr, Tollefson GD, Tran PV. Efficacy of olanzapine: an overview of pivotal clinical trials. J Clin Psychiatry 1997;58[suppl 10]:7-12.
3. Tran PV, Dellva MA, Tollefson GD, Beasley CM Jr, Potvin JH, Kiesler GM. Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia. J Clin Psychiatry 1997;58:205-11.
4. Grcevich SJ, Findling RL, Rowane WA, Friedman L, Schultz SC. Risperidone in the treatment of children and adolescents with schizophrenia: a retrospective study. J Child Adolesc Psychopharmacol 1996;6:251-7.
5. Findling RL, Grcevich SJ, Lopen I, Schultz SC. Antipsychotic medications in children and adolescents. J Clin Psychiatry 1996; 57[suppl 9]:19-23.
6. Frazier JA, Gordon CT, McKenna K, Lenane MC, Jih D, Rapoport JL. An open trial of clozapine in 11 adolescents with childhood-onset schizophrenia. J Am Acad Child Adolesc Psychiatry 1994;33:658-63.
7. Rane A, Wilson JT. Clinical pharmacokinetics in infants and children. Clin Pharmacokinet 1976;1:2-24.
8. Greenblatt DJ, Sellers EM, Shader RI. Drug disposition in old age. N Engl J Med 1982;306:1081-8.
9. McKenna K, Gordon C, Lenane M, Kaysen D, Fahey K, Rapoport J. Looking for childhood-onset schizophrenia: the first 71 cases screened. J Am Acad Child Adolesc Psychiatry 1994;33:636-44.
10. Kumra S, Jacobsen LK, Lenane M, Karp BL, Frazier JA, Smith AK, Bedwell J, Lee P, Malanga CJ, Hamburger S, Rapoport JL. Childhood-onset schizophrenia: an open-label comparison of olanzapine and clozapine. J Am Acad Child Adolesc Psychiatry 1998;37:377-85.
11. Overall J, Gorham D. The Brief Psychiatric Rating Scale. Psychiatry Res 1962;10:799-812.
12. Campbell M, Palig M. Subjective Treatment Emergent Symptoms Scale (STESS). Psychopharmacol Bull 1985;21:1063-82.
13. Rapoport J, Connors C, Reatig N. Rating scales and assessment instruments for use in pediatric psychopharmacology research. Psychopharmacol Bull 1985;21:713-1111.
14. Simpson G, Angus J. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand 1995;212:9-11.
15. Chiu JA, Franklin RB. Analysis and pharmacokinetics of olanzapine (LY170053) and two metabolites in rat plasma using reversed-phase HPLC with electrochemical detection. J Pharm Biomed Anal 1996;14:609-15.
16. Catlow JT, Barton RD, Clemens M, Gillespie TA, Goodwin M, Swanson SP. Analysis of olanzapine in human plasma utilizing reversed-phase high-performance liquid chromatography with electrochemical detection. J Chromatogr 1995;668:85-90.
17. DeVane CL. Principles of pharmacokinetics and pharmacodynamics. In: Schatzberg A, Nemeroff CB, eds. The American Psychiatric Press textbook of psychopharmacology. 2nd ed. Washington, DC: American Psychiatric Press, 1998:155-70.
18. Gibaldi M, Perrier D. Pharmacokinetics. 2nd ed. New York: Marcel Dekker, Inc., 1982.
19. Perry PN, Sanger T, Beasley C. Olanzapine plasma concentrations and clinical response in acutely ill schizophrenia patients. J Clin Psychopharmacol 1997;17:472-7.
20. Patel BR, Kurtz DL, Callaghan JT, Beasley CM Jr, Cerimele BJ, Bergstrom RF. Effects of smoking and gender on population pharmacokinetics of olanzapine in a phase III clinical trial. Annual Meeting of the American Association of Pharmaceutical Scientists [abstract]. Pharm Res 1996;13[9 suppl]:S408.
21. Tollefson GD, Beasley CM Jr, Tran PV, Street JS, Krueger JA, Tamura RN, Graffeo KA, Thieme ME. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 1997;154:457-65.
22. Ring BJ, Catlow J, Lindsay TJ, Gillespie T, Toskos LK, Cerimele BJ, Swanson SP, Hamman MA, Wrighton SA. Identification of the human cytochromes P450 responsible for the in vitro formation of the major oxidative metabolites of the antipsychotic agent olanzapine. J Pharmacol Exp Ther 1996;276:658-66.
23. Kassahun K, Mattiuz E, Nyhart E Jr. Obermeyer B, Gillespie T, Murphy A, Goodwin RM, Tupper D, Callaghan JT, Lemberger L. Disposition and biotransformation of the antipsychotic agent olanzapine in humans. Drug Metab Dispos 1997;25:81-93.
24. Patel M, Tang BK, Kalow W. (S)oxazepam glucuronidation is inhibited by ketoprofen and other substrates of UGT2B7. Pharmacogenetics 1995;5:43-9.
25. Bock KW, Scrunch D, Forster A, Grieve A, Maraca K, Brockmeier D, Eichelbaum M. The influence of environmental and genetic factors on CYP2D6, CYP1A2 and UDP-glucuronosyltransferases in man using sparteine, caffeine, and paracetamol as probes. Pharmacogenetics 1994;4:209-18.
26. Zyprexa® (olanzapine) product description. Indianapolis: Eli Lilly and Company, 1996.